| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma |
|
Medicine details |
|
| Medicine name | ipilimumab (Yervoy®) |
| Formulation | 5 mg/ml concentrate for solution for infusion |
| Reference number | 4918 |
| Indication | In combination with nivolumab is indicated for the first‑line treatment of adult patients with unresectable malignant pleural mesothelioma |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/06/2021 |
| NICE guidance | TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma |
| Commercial arrangement | PAS |